SGMOQ Insider Transactions — Page 8
1,473 retained open-market purchase and sale rows from SEC Forms 3, 4 and 5, newest first. This page shows rows 701–800; provenance stays internal.
| Insider profile | Role | Date | Transaction | Shares | Price |
|---|---|---|---|---|---|
| LANPHIER EDWARD O II | President & CEO | 2013-04-15 | Sale | 5,000.0 | $10.0 |
| Wolff Henry Ward | Exec VP & CFO | 2013-04-10 | Sale | 10,000.0 | $10.0 |
| Gregory Philip D | Vice President, Research & CSO | 2013-04-01 | Sale | 6,000.0 | $9.54 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2013-03-26 | Sale | 15,000.0 | $9.18 |
| Gregory Philip D | Vice President, Research & CSO | 2013-03-01 | Sale | 6,000.0 | $10.0 |
| Wolff Henry Ward | Exec VP & CFO | 2013-02-28 | Sale | 10,000.0 | $10.0 |
| LANPHIER EDWARD O II | President & CEO | 2013-02-28 | Sale | 25,000.0 | $10.0 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2013-02-26 | Sale | 15,000.0 | $8.64 |
| Gregory Philip D | Vice President, Research & CSO | 2013-02-01 | Sale | 6,000.0 | $9.53 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2013-01-28 | Sale | 15,000.0 | $9.68 |
| LANPHIER EDWARD O II | President & CEO | 2013-01-24 | Sale | 300.0 | $10.0 |
| Wolff Henry Ward | Exec VP & CFO | 2013-01-23 | Sale | 10,000.0 | $10.0 |
| LANPHIER EDWARD O II | President & CEO | 2013-01-23 | Sale | 8,300.0 | $10.0 |
| Gregory Philip D | Vice President, Research & CSO | 2013-01-02 | Sale | 6,000.0 | $6.05 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-12-26 | Sale | 15,000.0 | $5.92 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-12-26 | Sale | 2,000.0 | $5.94 |
| Gregory Philip D | Vice President, Research & CSO | 2012-12-10 | Sale | 12,000.0 | $6.0 |
| Gregory Philip D | Vice President, Research & CSO | 2012-12-10 | Sale | 12,000.0 | $4.92 |
| LARSON JOHN WILLIAM | Director | 2012-12-03 | Sale | 7,500.0 | $5.71 |
| LARSON JOHN WILLIAM | Director | 2012-12-03 | Sale | 400.0 | $5.7 |
| LARSON JOHN WILLIAM | Director | 2012-12-03 | Sale | 600.0 | $5.69 |
| LARSON JOHN WILLIAM | Director | 2012-12-03 | Sale | 100.0 | $5.63 |
| LARSON JOHN WILLIAM | Director | 2012-12-03 | Sale | 300.0 | $5.62 |
| LARSON JOHN WILLIAM | Director | 2012-12-03 | Sale | 1,805.0 | $5.61 |
| LARSON JOHN WILLIAM | Director | 2012-12-03 | Sale | 100.0 | $5.6 |
| LARSON JOHN WILLIAM | Director | 2012-12-03 | Sale | 3,195.0 | $5.54 |
| LARSON JOHN WILLIAM | Director | 2012-12-03 | Sale | 1,000.0 | $5.48 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-11-27 | Sale | 15,000.0 | $5.6 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-11-26 | Sale | 4,736.0 | $5.33 |
| LARSON JOHN WILLIAM | Director | 2012-11-01 | Sale | 15,000.0 | $5.52 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-10-26 | Sale | 5,000.0 | $5.72 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-10-26 | Sale | 15,000.0 | $5.69 |
| Gregory Philip D | VP, Therapeutic Dev. & CMO | 2012-10-17 | Sale | 6,000.0 | $6.0 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-10-15 | Sale | 1,500.0 | $5.62 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-10-15 | Sale | 1,500.0 | $5.62 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-10-15 | Sale | 300.0 | $5.69 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-10-15 | Sale | 500.0 | $5.69 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-10-15 | Sale | 186.0 | $5.7 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-10-15 | Sale | 14.0 | $5.71 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-10-15 | Sale | 1,000.0 | $5.72 |
| LARSON JOHN WILLIAM | Director | 2012-10-01 | Sale | 1,398.0 | $6.24 |
| LARSON JOHN WILLIAM | Director | 2012-10-01 | Sale | 1,940.0 | $6.22 |
| LARSON JOHN WILLIAM | Director | 2012-10-01 | Sale | 6,676.0 | $6.21 |
| LARSON JOHN WILLIAM | Director | 2012-10-01 | Sale | 58.0 | $6.2 |
| LARSON JOHN WILLIAM | Director | 2012-10-01 | Sale | 995.0 | $6.19 |
| LARSON JOHN WILLIAM | Director | 2012-10-01 | Sale | 1,258.0 | $6.18 |
| LARSON JOHN WILLIAM | Director | 2012-10-01 | Sale | 1,869.0 | $6.17 |
| LARSON JOHN WILLIAM | Director | 2012-10-01 | Sale | 506.0 | $6.16 |
| LARSON JOHN WILLIAM | Director | 2012-10-01 | Sale | 300.0 | $6.15 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-09-05 | Sale | 15,000.0 | $5.6 |
| LARSON JOHN WILLIAM | Director | 2012-09-04 | Sale | 100.0 | $5.35 |
| LARSON JOHN WILLIAM | Director | 2012-09-04 | Sale | 99.0 | $5.34 |
| LARSON JOHN WILLIAM | Director | 2012-09-04 | Sale | 300.0 | $5.33 |
| LARSON JOHN WILLIAM | Director | 2012-09-04 | Sale | 196.0 | $5.32 |
| LARSON JOHN WILLIAM | Director | 2012-09-04 | Sale | 7,603.0 | $5.32 |
| LARSON JOHN WILLIAM | Director | 2012-09-04 | Sale | 803.0 | $5.31 |
| LARSON JOHN WILLIAM | Director | 2012-09-04 | Sale | 2,702.0 | $5.3 |
| LARSON JOHN WILLIAM | Director | 2012-09-04 | Sale | 429.0 | $5.27 |
| LARSON JOHN WILLIAM | Director | 2012-09-04 | Sale | 1,068.0 | $5.26 |
| LARSON JOHN WILLIAM | Director | 2012-09-04 | Sale | 299.0 | $5.25 |
| LARSON JOHN WILLIAM | Director | 2012-09-04 | Sale | 100.0 | $5.24 |
| LARSON JOHN WILLIAM | Director | 2012-09-04 | Sale | 100.0 | $5.23 |
| LARSON JOHN WILLIAM | Director | 2012-09-04 | Sale | 500.0 | $5.22 |
| LARSON JOHN WILLIAM | Director | 2012-09-04 | Sale | 601.0 | $5.21 |
| LARSON JOHN WILLIAM | Director | 2012-09-04 | Sale | 100.0 | $5.2 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-08-27 | Sale | 250.0 | $5.23 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-08-27 | Sale | 200.0 | $5.22 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-08-27 | Sale | 1,000.0 | $5.22 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-08-27 | Sale | 550.0 | $5.21 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-08-27 | Sale | 200.0 | $5.17 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-08-27 | Sale | 1,630.0 | $5.16 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-08-27 | Sale | 1,170.0 | $5.15 |
| LARSON JOHN WILLIAM | Director | 2012-08-01 | Sale | 7,900.0 | $5.28 |
| LARSON JOHN WILLIAM | Director | 2012-08-01 | Sale | 1,500.0 | $5.27 |
| LARSON JOHN WILLIAM | Director | 2012-08-01 | Sale | 100.0 | $5.26 |
| LARSON JOHN WILLIAM | Director | 2012-08-01 | Sale | 100.0 | $5.24 |
| LARSON JOHN WILLIAM | Director | 2012-08-01 | Sale | 800.0 | $5.23 |
| LARSON JOHN WILLIAM | Director | 2012-08-01 | Sale | 1,500.0 | $5.22 |
| LARSON JOHN WILLIAM | Director | 2012-08-01 | Sale | 2,400.0 | $5.21 |
| LARSON JOHN WILLIAM | Director | 2012-08-01 | Sale | 700.0 | $5.2 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-07-27 | Sale | 15,000.0 | $5.6 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-07-26 | Sale | 500.0 | $4.99 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-07-26 | Sale | 500.0 | $5.02 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-07-26 | Sale | 1,500.0 | $5.04 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-07-26 | Sale | 1,500.0 | $5.09 |
| ANDO DALE G | VP, Therapeutic Dev. & CMO | 2012-07-26 | Sale | 1,000.0 | $5.12 |
| LARSON JOHN WILLIAM | Director | 2012-07-02 | Sale | 300.0 | $5.29 |
| LARSON JOHN WILLIAM | Director | 2012-07-02 | Sale | 100.0 | $5.28 |
| LARSON JOHN WILLIAM | Director | 2012-07-02 | Sale | 359.0 | $5.27 |
| LARSON JOHN WILLIAM | Director | 2012-07-02 | Sale | 2,500.0 | $5.26 |
| LARSON JOHN WILLIAM | Director | 2012-07-02 | Sale | 1,600.0 | $5.25 |
| LARSON JOHN WILLIAM | Director | 2012-07-02 | Sale | 4,100.0 | $5.24 |
| LARSON JOHN WILLIAM | Director | 2012-07-02 | Sale | 100.0 | $5.24 |
| LARSON JOHN WILLIAM | Director | 2012-07-02 | Sale | 100.0 | $5.23 |
| LARSON JOHN WILLIAM | Director | 2012-07-02 | Sale | 1,927.0 | $5.23 |
| LARSON JOHN WILLIAM | Director | 2012-07-02 | Sale | 100.0 | $5.22 |
| LARSON JOHN WILLIAM | Director | 2012-07-02 | Sale | 1,473.0 | $5.22 |
| LARSON JOHN WILLIAM | Director | 2012-07-02 | Sale | 100.0 | $5.22 |
| LARSON JOHN WILLIAM | Director | 2012-07-02 | Sale | 400.0 | $5.21 |
| LARSON JOHN WILLIAM | Director | 2012-07-02 | Sale | 100.0 | $5.21 |